Cargando…

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Antibody-based immunotherapy represents a promising strategy to eliminate chemorefractory leukemic cells in acute myeloid leukemia (AML). In this study, we evaluated a novel Fc-engineered antibody against CD157 (MEN1112) for its suitability as immunotherapy in AML. CD157 was expressed in 97% of prim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krupka, Christina, Lichtenegger, Felix S., Köhnke, Thomas, Bögeholz, Jan, Bücklein, Veit, Roiss, Michael, Altmann, Torben, Do, To Uyen, Dusek, Rachel, Wilson, Keith, Bisht, Arnima, Terrett, Jon, Aud, Dee, Pombo-Villar, Esteban, Rohlff, Christian, Hiddemann, Wolfgang, Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482610/ https://www.ncbi.nlm.nih.gov/pubmed/28415689 http://dx.doi.org/10.18632/oncotarget.16060

Ejemplares similares

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML
por: Köhnke, Thomas, et al.
Publicado: (2022)

Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
por: Schnorfeil, Frauke, et al.
Publicado: (2014)

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
por: Haubner, S., et al.
Publicado: (2018)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

P55. Dendritic cell vaccination for postremission therapy in AML
por: Lichtenegger, FS, et al.
Publicado: (2014)

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
por: Schnorfeil, Frauke M., et al.
Publicado: (2015)

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
por: Lichtenegger, Felix S, et al.
Publicado: (2020)

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
por: Daver, Naval, et al.
Publicado: (2021)

P20. Lack of T cell exhaustion in acute myeloid leukaemia
por: Schnorfeil, FM, et al.
Publicado: (2014)

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission
por: Beck, Barbara, et al.
Publicado: (2011)

CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2012)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
por: Pastore, Friederike, et al.
Publicado: (2014)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients
por: Bücklein, Veit, et al.
Publicado: (2016)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
por: Gaudio, Eugenio, et al.
Publicado: (2020)

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
por: Hänel, Gerulf, et al.
Publicado: (2021)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
por: Braciak, Todd A., et al.
Publicado: (2018)

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
por: Mohseni Nodehi, Sahar, et al.
Publicado: (2012)

A V(H)H-Fc Fusion Targeted to the Chloroplast Thylakoid Lumen Assembles and Neutralizes Enterohemorrhagic E. coli O157:H7
por: Chin-Fatt, Adam, et al.
Publicado: (2021)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Pore Development during the Carbonization Process of Lignin Microparticles Investigated by Small Angle X-ray Scattering
por: Rennhofer, Harald, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5g1uvhv38ftsfuevq4h04d068i